Cugene is a Boston-based clinical-stage biotechnology company with a deep pipeline of precision immunotherapies to transform the treatment landscape for autoimmune diseases and cancer.

CUG252 is a transformative, Phase 2–ready Treg-selective IL-2 engineered to redefine autoimmune disease treatment. Phase 1 studies in NHV and SLE patients met all primary, secondary and exploratory endpoints. CUG279 is a next-generation, multifunctional bispecific that integrates a TIL-targeting antibody with an eIL-2 and a proprietary masking technology to deliver synergistic TIL reinvigoration, activation, and expansion at the tumor site, targeting IND early 2026.